Anuncio de seguridad El 26 de julio, 2013, La Administración de Alimentos y Medicamentos de Estados Unidos (FDA por sus siglas en inglés) está tomando varias medidas relacionadas con las tabletas orales de Nizoral (ketoconazol), entre ellas limitar el uso del medicamento, advertir que puede causar lesiones severas al hÃgado y problemas de las glándulas…
Current Drug Shortages Index
Acetylcysteine Inhalation Solution Acyclovir Sodium Injection (initial posting 11/13/2012)  Alteplase (Cathflo Activase) (initial posting 1/27/2012) Amikacin Injection  7/22/2013Aminocaproic Acid Injection (initial posting 3/8/2013)  Aminophylline (initial posting 12/10/2012) Ammonium Chloride Injection (initial posting 3/8/2013) Amytal Sodium Injection (initial posting date 1/31/2013) Atracurium Besylate (initial posting 2/27/2012) Atropine Sulfate Injection  back to top Bacteriostatic 0.9% Sodium Chloride (initial posting 9/10/2012) Barium Sulfate for Suspension (initial posting 10/12/2012)  7/28/2013Bismuth Subsalicylate; Metronidazole; Tetracycline Hydrochloride (Helidac) (initial posting…
FDA Drug Safety Communication: FDA approves label changes for antimalarial drug mefloquine hydrochloride due to risk of serious psychiatric and nerve side effects
<!– –> <!– Page Last Updated: 07/29/2013 –> Page Last Updated: 07/29/2013 <!– –> Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
FDA Drug Safety Communication: FDA limits usage of Nizoral (ketoconazole) oral tablets due to potentially fatal liver injury and risk of drug interactions and adrenal gland problems
Safety Announcement [7-26-2013]   The U.S. Food and Drug Administration (FDA) is taking several actions related to Nizoral (ketoconazole) oral tablets, including limiting the drug’s use, warning that it can cause severe liver injuries and adrenal gland problems and advising that it can lead to harmful drug interactions with other medications. FDA has approved label changes…
June 2013: Additions and Deletions to the Drug Product List (PDF)
%PDF-1.7% 5108 0 objendobj 5125 0 obj/Filter/FlateDecode/ID[]/Index[5108 36]/Info 5107 0 R/Length 89/Prev 143728/Root 5109 0 R/Size 5144/Type/XRef/W[1 2 1]stream hbbd“b` H
FDA Drug Safety Communication: FDA approves label changes to include intestinal problems (sprue-like enteropathy) linked to blood pressure medicine olmesartan medoxomil
Data Summary Olmesartan medoxomil is an angiotensin II receptor blocker (ARB) that was approved on April 25, 2002, for the treatment of hypertension, alone or with other antihypertensive agents. The current olmesartan drug labels include diarrhea in the Adverse Reactions section. FDA evaluated adverse event reports received by FDA’s Adverse Event Reporting System (FAERS), published…
FDA Drug Safety Communication: FDA is investigating two deaths following injection of long-acting antipsychotic Zyprexa Relprevv (olanzapine pamoate)
<!– –> <!– Page Last Updated: 06/18/2013 –> Page Last Updated: 06/18/2013 <!– –> Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
May 2013: Additions and Deletions to the Drug Product List
%PDF-1.5% 3950 0 objendobj 3969 0 obj/Filter/FlateDecode/ID[]/Index[3950 41]/Info 3949 0 R/Length 95/Prev 173112/Root 3951 0 R/Size 3991/Type/XRef/W[1 2 1]stream hbbd“b`7@’$W$@ HBĺ$惈c d C7HQL,F /T
FDA Adverse Event Reporting System (FAERS) Statistics
<!– –> <!– Page Last Updated: 06/11/2013 –> Page Last Updated: 06/11/2013 <!– –> Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Update on Main Street Family Pharmacy Products: Samples of injectable methylprednisolone acetate test positive for microbial contamination
<!– –> <!– Page Last Updated: 06/07/2013 –> Page Last Updated: 06/07/2013 <!– –> Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.